J Neuromuscul Dis 2018; 5(4):407-417
A new line of dystrophic mdx mice on the DBA/2J (D2) background has emerged as a candidate to study the efficacy of therapeutic approaches for Duchenne muscular dystrophy (DMD). These mice harbor genetic polymorphisms that appear to increase the severity of the dystropathology, with disease modifiers that also occur in DMD patients, making them attractive for efficacy studies and drug development. This workshop aimed at collecting and consolidating available data on the pathological features and the natural history of these new D2/mdx mice, for comparison with classic mdx mice and controls, and to identify gaps in information and their potential value. The overall aim is to establish guidance on how to best use the D2/mdx mouse model in preclinical studies.
Gordish-Dressman, Heather; Willmann, Raffaella; Dalle Pazze, Laura; Kreibich, Arati; van Putten, Maaike; Heydemann, Ahlke; Bogdanik, Laurent P.; Lutz, Cathleen; Davies, Kay; Demonbruen, Alexis R; Duan, Dongsheng; Elsey, David; Fukada, So-Ichiro; Girgenrath, Mahasweta; Patrick Gonzalez, J; Grounds, Miranda D; Nichols, Andy; Partridge, Terry; Passini, Marco; Sanarica, Francesca; Schnell, Frederick J; Wells, Dominic J; Yokota, Toshifumi; Young, Courtney S; Zhong, Zhong; Spurney, Christopher; Spencer, Melissa; De Luca, Annamaria; Nagaraju, Kanneboyina; and Aartsma-Rus, Annemieke, ""Of Mice and Measures": A Project to Improve How We Advance Duchenne Muscular Dystrophy Therapies to the Clinic." (2018). Faculty Research 2018. 226.